Bionime Corp (4737) - Net Assets
Based on the latest financial reports, Bionime Corp (4737) has net assets worth NT$1.86 Billion TWD (≈ $58.50 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$5.58 Billion ≈ $175.95 Million USD) and total liabilities (NT$3.73 Billion ≈ $117.44 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 4737 financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$1.86 Billion |
| % of Total Assets | 33.25% |
| Annual Growth Rate | 7.47% |
| 5-Year Change | -8.78% |
| 10-Year Change | -25.68% |
| Growth Volatility | 27.13 |
Bionime Corp - Net Assets Trend (2009–2024)
This chart illustrates how Bionime Corp's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Bionime Corp for the complete picture of this company's asset base.
Annual Net Assets for Bionime Corp (2009–2024)
The table below shows the annual net assets of Bionime Corp from 2009 to 2024. For live valuation and market cap data, see 4737 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.89 Billion ≈ $59.51 Million |
-5.23% |
| 2023-12-31 | NT$1.99 Billion ≈ $62.80 Million |
-4.20% |
| 2022-12-31 | NT$2.08 Billion ≈ $65.55 Million |
+0.21% |
| 2021-12-31 | NT$2.08 Billion ≈ $65.41 Million |
+0.26% |
| 2020-12-31 | NT$2.07 Billion ≈ $65.24 Million |
+1.17% |
| 2019-12-31 | NT$2.05 Billion ≈ $64.49 Million |
+2.70% |
| 2018-12-31 | NT$1.99 Billion ≈ $62.79 Million |
-4.07% |
| 2017-12-31 | NT$2.08 Billion ≈ $65.46 Million |
-19.68% |
| 2016-12-31 | NT$2.59 Billion ≈ $81.50 Million |
+1.77% |
| 2015-12-31 | NT$2.54 Billion ≈ $80.08 Million |
+88.68% |
| 2014-12-31 | NT$1.35 Billion ≈ $42.44 Million |
+25.82% |
| 2013-12-31 | NT$1.07 Billion ≈ $33.73 Million |
+6.96% |
| 2012-12-31 | NT$1.00 Billion ≈ $31.54 Million |
-7.75% |
| 2011-12-31 | NT$1.09 Billion ≈ $34.19 Million |
+6.75% |
| 2010-12-31 | NT$1.02 Billion ≈ $32.02 Million |
+58.59% |
| 2009-12-31 | NT$640.89 Million ≈ $20.19 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Bionime Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 90.4% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$13.06 Million | 0.69% |
| Common Stock | NT$610.39 Million | 32.47% |
| Other Components | NT$1.26 Billion | 66.84% |
| Total Equity | NT$1.88 Billion | 100.00% |
Bionime Corp Competitors by Market Cap
The table below lists competitors of Bionime Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
First Capital Inc
NASDAQ:FCAP
|
$151.22 Million |
|
Mineralbrunnen Überkingen-Teinach GmbH & Co. KGaA
F:MUT
|
$151.25 Million |
|
TONGDAO LIEP.GR. DL-0001
F:6WT
|
$151.27 Million |
|
Solstice Minerals Ltd
AU:SLS
|
$151.27 Million |
|
Stratus Properties Inc
NASDAQ:STRS
|
$151.18 Million |
|
Barton Gold Holdings Ltd
AU:BGD
|
$151.16 Million |
|
Golden Long Teng Development Co Ltd
TWO:3188
|
$151.15 Million |
|
Suheung Capsul
KO:008490
|
$151.08 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bionime Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,986,032,000 to 1,879,978,000, a change of -106,054,000 (-5.3%).
- Net loss of 127,216,000 reduced equity.
- Dividend payments of 122,003,000 reduced retained earnings.
- New share issuances of 6,929,000 increased equity.
- Other comprehensive income decreased equity by 459,614,999.
- Other factors increased equity by 595,850,999.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-127.22 Million | -6.77% |
| Dividends Paid | NT$122.00 Million | -6.49% |
| Share Issuances | NT$6.93 Million | +0.37% |
| Other Comprehensive Income | NT$-459.61 Million | -24.45% |
| Other Changes | NT$595.85 Million | +31.69% |
| Total Change | NT$- | -5.34% |
Book Value vs Market Value Analysis
This analysis compares Bionime Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.21x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 4.28x to 2.21x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | NT$14.51 | NT$62.10 | x |
| 2010-12-31 | NT$24.86 | NT$62.10 | x |
| 2011-12-31 | NT$22.02 | NT$62.10 | x |
| 2012-12-31 | NT$20.34 | NT$62.10 | x |
| 2013-12-31 | NT$22.10 | NT$62.10 | x |
| 2014-12-31 | NT$27.58 | NT$62.10 | x |
| 2015-12-31 | NT$44.51 | NT$62.10 | x |
| 2016-12-31 | NT$36.84 | NT$62.10 | x |
| 2017-12-31 | NT$31.49 | NT$62.10 | x |
| 2018-12-31 | NT$31.18 | NT$62.10 | x |
| 2019-12-31 | NT$31.62 | NT$62.10 | x |
| 2020-12-31 | NT$31.13 | NT$62.10 | x |
| 2021-12-31 | NT$30.96 | NT$62.10 | x |
| 2022-12-31 | NT$30.70 | NT$62.10 | x |
| 2023-12-31 | NT$29.50 | NT$62.10 | x |
| 2024-12-31 | NT$28.06 | NT$62.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bionime Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -6.77%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -6.58%
- • Asset Turnover: 0.33x
- • Equity Multiplier: 3.08x
- Recent ROE (-6.77%) is below the historical average (6.35%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 21.10% | 14.42% | 1.05x | 1.39x | NT$71.15 Million |
| 2010 | 13.39% | 11.23% | 0.94x | 1.27x | NT$34.41 Million |
| 2011 | 16.51% | 12.13% | 0.52x | 2.63x | NT$70.60 Million |
| 2012 | 3.41% | 2.38% | 0.40x | 3.63x | NT$-65.95 Million |
| 2013 | 8.40% | 5.76% | 0.35x | 4.23x | NT$-17.14 Million |
| 2014 | 4.03% | 3.56% | 0.33x | 3.46x | NT$-80.41 Million |
| 2015 | 3.89% | 6.14% | 0.35x | 1.80x | NT$-155.40 Million |
| 2016 | 6.91% | 10.27% | 0.37x | 1.80x | NT$-79.89 Million |
| 2017 | 7.20% | 8.22% | 0.42x | 2.11x | NT$-58.15 Million |
| 2018 | 6.43% | 6.38% | 0.44x | 2.30x | NT$-71.09 Million |
| 2019 | 5.20% | 4.89% | 0.49x | 2.16x | NT$-98.00 Million |
| 2020 | 3.02% | 3.74% | 0.37x | 2.17x | NT$-144.13 Million |
| 2021 | 4.22% | 4.73% | 0.41x | 2.21x | NT$-119.52 Million |
| 2022 | 4.39% | 4.12% | 0.44x | 2.40x | NT$-116.22 Million |
| 2023 | 0.31% | 0.35% | 0.33x | 2.67x | NT$-192.39 Million |
| 2024 | -6.77% | -6.58% | 0.33x | 3.08x | NT$-315.21 Million |
Industry Comparison
This section compares Bionime Corp's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $1,551,884,000
- Average return on equity (ROE) among peers: 10.03%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bionime Corp (4737) | NT$1.86 Billion | 21.10% | 2.01x | $151.21 Million |
| St.Shine Optical Co Ltd (1565) | $966.82 Million | 24.11% | 0.40x | $164.40 Million |
| Maxigen Biotech Inc (1783) | $369.25 Million | -9.77% | 0.32x | $109.91 Million |
| SciVision Biotech Inc (1786) | $363.70 Million | 14.07% | 0.11x | $135.56 Million |
| Bioteque (4107) | $2.80 Billion | 15.38% | 0.38x | $252.17 Million |
| Chi Sheng Chemical (4111) | $1.05 Billion | 4.04% | 0.44x | $55.51 Million |
| BenQ Medical Technology (4116) | $1.09 Billion | 6.10% | 0.54x | $56.09 Million |
| Pacific Hospital Supply Co Ltd (4126) | $2.71 Billion | 14.28% | 0.40x | $181.84 Million |
| Vizionfocus Inc. (4771) | $2.02 Billion | 15.48% | 0.59x | $347.59 Million |
| Formosa Optical Technology Co Ltd (5312) | $2.60 Billion | 6.55% | 1.44x | $183.92 Million |
About Bionime Corp
Bionime Corporation designs, manufactures, and sells medical instruments in China, Switzerland, the United States, Belarus, Algeria, the United Arab Emirates, Egypt, and internationally. The company manufactures and sells blood glucose meters and test strips to medical equipment companies, pharmacies, and hospitals, as well as offers blood glucose monitoring devices and systems under the RIGHTEST… Read more